FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2980106908> ?p ?o ?g. }

• W2980106908 endingPage "427" @default.
• W2980106908 startingPage "427" @default.
• W2980106908 abstract "Abstract Background: Ambulatory cancer patients at high-risk for venous thromboembolism (VTE) can be identified using a validated risk score. We evaluated the benefit of outpatient thromboprophylaxis with dalteparin in such high-risk patients in a multicenter randomized controlled trial. Methods: Cancer patients at high risk for VTE (Khorana score ≥3) and initiating a new systemic chemotherapy regimen were screened for VTE and, if negative, randomized to either dalteparin 5000 units daily subcutaneously or no prophylactic anticoagulation for 12 weeks. Subjects in both arms were screened with lower extremity ultrasounds every 4 weeks on study. Primary efficacy endpoint was any VTE over 12 weeks and primary safety endpoint was clinically relevant bleeding events over 13 weeks. The study was terminated due to poor accrual. Results: Of 117 enrolled patients, 19 were not randomized due to the presence of VTE on initial screening (N=10, 8.5%) or for other reasons (N=9). The mean age was 59 years with 46% female and 54% male, similar in both arms. The most common primary sites of cancer were pancreas, gastro-esophageal junction, lung and lymphoma. Over three-fourths of patients in each arm had an ECOG performance status of 0 or 1.Of 98 patients randomized, VTE occurred in 12% (N=6/50) of patients on the dalteparin arm and 21% (N=10/48) on the control arm (hazard ratio, HR 0.69, 95% CI 0.23-1.89) (absolute risk reduction 9%, relative risk reduction 42%, number needed to treat = 12). Major bleeding was similar (N=1) in each arm but clinically relevant bleeding was higher in the dalteparin arm (N=7 versus 1 in the control arm) (HR = 7.0, 95% CI 1.2-131.6). There was no difference in overall survival. Conclusions: Thromboprophylaxis is associated with a non-significant reduced risk of VTE with no effect on major bleeding or survival but increased risk of clinically relevant bleeding in this underpowered study population. The Khorana score successfully identifies patients with high incidence of VTE both at baseline and during study. The high incidence of baseline VTE suggests that consideration should be given to screening high-risk patients in clinical practice prior to starting systemic therapy. Future studies should continue to focus on risk-adapted approaches to reduce the burden of VTE in cancer. (Funded by NIH/NHLBI R01HL095109; clinicaltrials.gov identifier: NCT00876915). Table 1. Baseline Characteristics of Patients Enrolled in the PHACS trial Dalteparin Observation Total Enrolled (n) Baseline VTE, n (%) DVT PE Other reasons for not randomizing Randomized (n) Age, mean (SD), y --- --- --- --- --- 50 60 (10) --- --- --- --- --- 48 58 (12) 117 10 (9%) 6* (5%) 4 (3%) 9 98 59 (11) Gender, n (%) Female 21 (42%) 24 (50%) 45 (46%) Male 29 (58%) 24 (50%) 53 (54%) Primary Tumor Site, No. (%) Gynecologic 4 (8%) 4 (8%) 8 (8%) Colorectal 1 (2%) 3 (6%) 4 (4%) GE junction 8 (16%) 4 (8%) 12 (25%) Lung 6 (12%) 7(15%) 13 (27%) Genitourinary 2 (4%) 0 (0%) 2 (2%) Lymphoma 5 (10%) 2 (4%) 7 (15%) Breast 1 (2%) 1 (2%) 2 (2%) Pancreatic 19 (38%) 17 (35%) 36 (37%) Gastric 4 (8%) 6 (13%) 10 (10%) Other 0 (0%) 4 (8%) 4 (4%) Previous history of VTE, n (%) 4 (8%) 2 (4%) 6 (6%) *NOTE: 1 subject had both DVT and PE at baseline screening Abbreviations: DVT, deep vein thrombosis; PE pulmonary embolism; VTE, venous thromboembolism; ECOG: Eastern Cooperative Oncology Group Figure 1. Cumulative Incidence Curves for the Primary Efficacy Outcome in the Intention-to-Treat Population, According to Study Arm. Figure 1. Cumulative Incidence Curves for the Primary Efficacy Outcome in the Intention-to-Treat Population, According to Study Arm. Disclosures Khorana: Leo Pharma: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Pfizer: Consultancy, Honoraria; Janssen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Boehringer-Ingelheim: Consultancy, Honoraria; Daiichi Sankyo: Consultancy, Honoraria; sanofi: Consultancy, Honoraria. Off Label Use: Randomized trial of dalteparin as prophylaxis. The drug is approved for treatment of cancer-associated thrombosis but not for prophylaxis.. Francis:Eisai: Consultancy, Research Funding; Portola: Consultancy, Honoraria; NHLBI: Consultancy; Lilly: Consultancy. Kuderer:Hospira: Consultancy; Janssen: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Daiichi Sankyo: Consultancy. Carrier:Leo Pharma: Consultancy, Research Funding; BMS: Research Funding; Bayer: Consultancy, Honoraria; Pfizer: Consultancy. Ortel:Instrumentation Laboratory: Consultancy; Instrumentation Laboratory: Research Funding; Eisai: Research Funding; Daiichi Sankyo: Consultancy. Wun:Janssen: Consultancy. Iyer:Ipsen Pharmaceuticals: Consultancy; Genentec: Research Funding; Bristol Myers Squibb: Honoraria. Lyman:Amgen: Research Funding." @default.
• W2980106908 created "2019-10-18" @default.
• W2980106908 creator A5000127045 @default.
• W2980106908 creator A5000669662 @default.
• W2980106908 creator A5039576853 @default.
• W2980106908 creator A5041299305 @default.
• W2980106908 creator A5054511215 @default.
• W2980106908 creator A5055725897 @default.
• W2980106908 creator A5057507865 @default.
• W2980106908 creator A5069172766 @default.
• W2980106908 creator A5073060840 @default.
• W2980106908 date "2015-12-03" @default.
• W2980106908 modified "2023-09-30" @default.
• W2980106908 title "Dalteparin Thromboprophylaxis in Cancer Patients at High Risk for Venous Thromboembolism: A Randomized Trial" @default.
• W2980106908 doi "https://doi.org/10.1182/blood.v126.23.427.427" @default.
• W2980106908 hasPublicationYear "2015" @default.
• W2980106908 type Work @default.
• W2980106908 sameAs 2980106908 @default.
• W2980106908 citedByCount "12" @default.
• W2980106908 countsByYear W29801069082016 @default.
• W2980106908 countsByYear W29801069082017 @default.
• W2980106908 countsByYear W29801069082018 @default.
• W2980106908 countsByYear W29801069082020 @default.
• W2980106908 countsByYear W29801069082021 @default.
• W2980106908 crossrefType "journal-article" @default.
• W2980106908 hasAuthorship W2980106908A5000127045 @default.
• W2980106908 hasAuthorship W2980106908A5000669662 @default.
• W2980106908 hasAuthorship W2980106908A5039576853 @default.
• W2980106908 hasAuthorship W2980106908A5041299305 @default.
• W2980106908 hasAuthorship W2980106908A5054511215 @default.
• W2980106908 hasAuthorship W2980106908A5055725897 @default.
• W2980106908 hasAuthorship W2980106908A5057507865 @default.
• W2980106908 hasAuthorship W2980106908A5069172766 @default.
• W2980106908 hasAuthorship W2980106908A5073060840 @default.
• W2980106908 hasConcept C120195587 @default.
• W2980106908 hasConcept C121608353 @default.
• W2980106908 hasConcept C126322002 @default.
• W2980106908 hasConcept C141071460 @default.
• W2980106908 hasConcept C168563851 @default.
• W2980106908 hasConcept C203092338 @default.
• W2980106908 hasConcept C207103383 @default.
• W2980106908 hasConcept C2778336483 @default.
• W2980106908 hasConcept C2781413609 @default.
• W2980106908 hasConcept C35785553 @default.
• W2980106908 hasConcept C44249647 @default.
• W2980106908 hasConcept C71924100 @default.
• W2980106908 hasConcept C82789193 @default.
• W2980106908 hasConceptScore W2980106908C120195587 @default.
• W2980106908 hasConceptScore W2980106908C121608353 @default.
• W2980106908 hasConceptScore W2980106908C126322002 @default.
• W2980106908 hasConceptScore W2980106908C141071460 @default.
• W2980106908 hasConceptScore W2980106908C168563851 @default.
• W2980106908 hasConceptScore W2980106908C203092338 @default.
• W2980106908 hasConceptScore W2980106908C207103383 @default.
• W2980106908 hasConceptScore W2980106908C2778336483 @default.
• W2980106908 hasConceptScore W2980106908C2781413609 @default.
• W2980106908 hasConceptScore W2980106908C35785553 @default.
• W2980106908 hasConceptScore W2980106908C44249647 @default.
• W2980106908 hasConceptScore W2980106908C71924100 @default.
• W2980106908 hasConceptScore W2980106908C82789193 @default.
• W2980106908 hasIssue "23" @default.
• W2980106908 hasLocation W29801069081 @default.
• W2980106908 hasOpenAccess W2980106908 @default.
• W2980106908 hasPrimaryLocation W29801069081 @default.
• W2980106908 hasRelatedWork W1624195330 @default.
• W2980106908 hasRelatedWork W1972249949 @default.
• W2980106908 hasRelatedWork W2028894998 @default.
• W2980106908 hasRelatedWork W2156294597 @default.
• W2980106908 hasRelatedWork W2333357360 @default.
• W2980106908 hasRelatedWork W2404939445 @default.
• W2980106908 hasRelatedWork W2415167834 @default.
• W2980106908 hasRelatedWork W2904033503 @default.
• W2980106908 hasRelatedWork W2999904863 @default.
• W2980106908 hasRelatedWork W4237621402 @default.
• W2980106908 hasVolume "126" @default.
• W2980106908 isParatext "false" @default.
• W2980106908 isRetracted "false" @default.
• W2980106908 magId "2980106908" @default.
• W2980106908 workType "article" @default.